ライフサイエンスコーパス: rifabutin

1 R, 0.43; 95% CI, 0.27-0.69; P=.0003), versus rifabutin.

2 r azithromycin and $74000 per QALY saved for rifabutin.

3 alone and in combination with rifampicin or rifabutin.

4 e precluded comparisons for tetracycline and rifabutin.

5 g or moderate inducers such as rifampicin or rifabutin.

6 25 microg/ml; ethambutol, 20 microg/ml; and rifabutin, 0.5 microg/ml.

7 s were susceptible to clarithromycin (100%), rifabutin (100%), ethambutol (92%), and sulfamethoxazole

8 5 (amoxicillin, 3 g; omeprazole, 120 mg; and rifabutin, 150 mg) versus active comparator (amoxicillin

9 The patients were assigned to receive rifabutin (300 mg daily), azithromycin (1200 mg weekly),

10 n and daily ethambutol (15 mg/kg/day), daily rifabutin (300 mg/day), and initial twice weekly (BIW) s

11 a combination of fluconazole, 200 mg/d, and rifabutin, 300 mg/d, for 2 weeks; and then rifabutin, 30

12 d rifabutin, 300 mg/d, for 2 weeks; and then rifabutin, 300 mg/d, for the final 2 weeks of the study.

13 romycin, TIW ethambutol (25 mg/kg/dose), TIW rifabutin (600 mg/dose), and initial BIW streptomycin.

14 infection at one year was 15.3 percent with rifabutin, 7.6 percent with azithromycin, and 2.8 percen

15 doxycycline, clarithromycin, ethambutol, and rifabutin against M chimaera.

16 when two-drug prophylaxis was compared with rifabutin alone (hazard ratio, 0.28; P<0.001) or azithro

17 risk of developing PCP than those receiving rifabutin alone (n=236; p=0.008).

18 s (P=.06), and 11% for patients treated with rifabutin alone (P=.84).

19 he efficacy and safety of clarithromycin and rifabutin alone and in combination for prevention of Myc

20 7% of those randomized to clarithromycin or rifabutin alone or in combination, respectively; time-ad

21 Compared with rifabutin alone, hazard ratio for azithromycin was 0.54

22 7 ng.h/mL; P less than or equal to 0.05) for rifabutin and 216% (959 +/- 529 ng.h/mL compared with 24

23 xicillin, clarithromycin, metronidazole, and rifabutin and 57 isolates and FFPE tissue for levofloxac

24 ly azithromycin is more effective than daily rifabutin and infrequently selects for resistant isolate

25 increased the plasma concentrations of both rifabutin and LM565.

26 ntly increases the systemic exposure of both rifabutin and LM565.

27 ive (16%) of 31 isolates were susceptible to rifabutin and more than 90% were likely to be sensitive

28 We report 2.5 A resolution structures of rifabutin and rifapentin complexed with the Thermus ther

29 In contrast, rifampin, rifabutin and rifapentine administered with vancomycin y

30 ponse to tuberculosis antibiotics (rifampin, rifabutin and rifapentine) were compared in primary huma

31 iotics, including two rifamycin derivatives, rifabutin and rifapentine, and streptolydigin and sorang

32 ascertain concentrations of fluconazole and rifabutin and the 25-desacetyl metabolite of rifabutin,

33 foreign body osteomyelitis, suggesting that rifabutin and/or rifapentine may be alternatives to rifa

34 resistance to clarithromycin, levofloxacin, rifabutin, and tetracycline from clinical isolates and f

35 ive randomised trial comparing azithromycin, rifabutin, and the two drugs in combination for preventi

36 id and rifampicin (arm 1), 2) pretomanid and rifabutin (arm 2), or 3) rifampicin and ethambutol (stan

37 Intermittent rifabutin-based therapy for HIV-related TB was well tole

38 depending on suspected resistance, reserving rifabutin-based triple and high-dose dual amoxicillin pr

39 Rifabutin-based triple therapy (RHB-105) for Helicobacte

40 The DDI with rifabutin can be overcome by administering LA cabotegrav

41 nt (n = 1,075) and a study of a twice-weekly rifabutin-containing regimen for human immunodeficiency

42 nts appeared highest with the pretomanid and rifabutin-containing regimen.

43 Two of the 214 patients taking rifabutin developed cryptosporidiosis vs 33 of the 805 n

44 combination therapy were more effective than rifabutin for prevention of MAC disease, but combination

45 ndomized to receive 5 days of treatment with rifabutin, G-CSF, or both agents.

46 the azithromycin group was half that in the rifabutin group (hazard ratio, 0.53; P = 0.008).

47 ambutol hydrochloride, and streptomycin (and rifabutin, if sensitivity testing included it), and, if

48 with rpoB D516V had less cross-resistance to rifabutin, increased baseline resistance to other drugs,

49 he antimycobacterial drugs clarithromycin or rifabutin, induced a decrease in bacterial numbers that

50 ts associated with systemic corticosteroids, rifabutin-induced uveitis, cocaine-related retinal hemor

51 ntin, and contradictory to the steric model, rifabutin inhibits formation of the first and second pho

52 reated under direct supervision with 2 mo of rifabutin, isoniazid, pyrazinamide, and ethambutol (give

53 rifabutin and the 25-desacetyl metabolite of rifabutin, LM565.

54 ctable drug formulations of the anti-TB drug rifabutin made of biodegradable polymers and biocompatib

55 combination of amikacin, clarithromycin, and rifabutin may be the most efficacious therapy for the tr

56 either alone (n=233) or in combination with rifabutin (n=224), had a 45% lower risk of developing PC

57 resistant to tetracycline (culture) and 1 to rifabutin (NGS).

58 Rifampin, rifabutin or rifapentine administered with vancomycin yi

59 Rifabutin or rifapentine with vancomycin were as active

60 After 4 weeks of infection, rifampin, rifabutin, or rifapentine were administered, alone or wi

61 Rifabutin plus azithromycin is even more effective but i

62 l program), followed by 4 mo of twice-weekly rifabutin plus isoniazid.

63 twice daily, ethambutol, rifampin (RMP), or rifabutin (RBT) and initial streptomycin, and they were

64 itonavir (LPV/r) used with rifampin (RIF) or rifabutin (RBT) are limited.

65 f M. abscessus to sublethal doses of RIF and Rifabutin (RBT), a close analog of RIF, results in an ~2

66 unknown hyperactivity of the old antibiotic, rifabutin (RBT), against highly resistant Acinetobacter

67 Rifampicin, but not rifabutin, reduces pretomanid exposures.

68 Rifabutin regimens should be restricted to patients who

69 No rifabutin resistance was detected.

70 This work focuses on the interaction of rifabutin (RFB), a naphthalenic ansamycin, with membrane

71 luding front line drugs rifampicin (RIF) and rifabutin (RFB), resulting in altered host defense and d

72 ryptosporidiosis vs 33 of the 805 not taking rifabutin (RH, 0.15 [95% CI, 0.04-0.62]; P=.01).

73 In the current study, we evaluated rifabutin, rifapentine and rifampin, with and without va

74 nfirmed that the binding sites for rifampin, rifabutin, rifapentine, and sorangicin A are shared, whe

75 n treatment with the azithromycin-ethambutol-rifabutin standard of care (SOC).

76 nsferase, the frontrunners are equipotent to rifabutin, suggesting superior clinical utility since th

77 We chemically reengineered rifabutin to enhance its potency against M. abscessus by

78 ient improved with prolonged doxycycline and rifabutin treatment.

79 Rifabutin use was associated with a decreased relative r

80 e more likely to have histories of diarrhea, rifabutin use, or antifungal therapy.

81 tronidazole, levofloxacin, tetracycline, and rifabutin using agar dilution and NGS targeted to 23S rR

82 54 (95% CI 0.32-0.94), for azithromycin plus rifabutin was 0.55 (0.32-0.94), and for regimens contain

83 on and to reproduce DDIs with rifampicin and rifabutin was first verified against available observed

84 The moderate inducer rifabutin was predicted to reduce the AUC of LA cabotegr

85 Rifabutin was recommended in place of rifampin during tr

86 Clarithromycin and rifabutin were highly protective against development of

87 ss to delamanid, bedaquiline, linezolid, and rifabutin, when appropriate, must be accelerated along w

88 ompounds, with a single misclassification of rifabutin, which was incorrectly categorized as affectin

89 susceptible to clarithromycin, amikacin, and rifabutin, while resistance was observed for tetracyclin

90 eported in both the efficacy and toxicity of rifabutin with concomitant fluconazole therapy.